These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23880541)

  • 1. Investigation into the functional impact of the vancomycin C-ring aryl chloride.
    Pinchman JR; Boger DL
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4817-9. PubMed ID: 23880541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the role of the vancomycin e-ring aryl chloride: selective divergent synthesis and evaluation of alternatively substituted E-ring analogues.
    Pinchman JR; Boger DL
    J Med Chem; 2013 May; 56(10):4116-24. PubMed ID: 23617725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of selected key methyl ether derivatives of vancomycin aglycon.
    Crane CM; Pierce JG; Leung SS; Tirado-Rives J; Jorgensen WL; Boger DL
    J Med Chem; 2010 Oct; 53(19):7229-35. PubMed ID: 20853900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of vancomycin aglycon analogues that bear modifications in the N-terminal D-leucyl amino acid.
    Crane CM; Boger DL
    J Med Chem; 2009 Mar; 52(5):1471-6. PubMed ID: 19209892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A stepwise dechlorination/cross-coupling strategy to diversify the vancomycin 'in-chloride'.
    Wadzinski TJ; Gea KD; Miller SJ
    Bioorg Med Chem Lett; 2016 Feb; 26(3):1025-1028. PubMed ID: 26725950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Small change, large effect--a new vancomycin derivative against MRSA].
    Holzgrabe U; Bennack E
    Pharm Unserer Zeit; 2006; 35(5):386. PubMed ID: 17009779
    [No Abstract]   [Full Text] [Related]  

  • 7. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    JAMA; 1997 Sep; 278(11):891-2. PubMed ID: 9302229
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibiotic activities and affinities for bacterial cell wall analogue of N-demethylvancomycin and its derivatives.
    Yan H; Qi D; Cheng X; Song Z; Li W; He B
    J Antibiot (Tokyo); 1998 Aug; 51(8):750-6. PubMed ID: 9766467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detecting vancomycin intermediate Staphylococcus aureus.
    Commun Dis Rep CDR Wkly; 1997 Nov; 7(47):417, 20. PubMed ID: 9401190
    [No Abstract]   [Full Text] [Related]  

  • 11. The first glycopeptide-intermediate Staphylococcus aureus in Oman.
    Elhag KM; Al Jardani AK; Al Yaqubi FM; Mohsin N
    Clin Microbiol Infect; 2000 Mar; 6(3):173-4. PubMed ID: 11168103
    [No Abstract]   [Full Text] [Related]  

  • 12. Desleucyl-Oritavancin with a Damaged d-Ala-d-Ala Binding Site Inhibits the Transpeptidation Step of Cell-Wall Biosynthesis in Whole Cells of Staphylococcus aureus.
    Kim SJ; Singh M; Sharif S; Schaefer J
    Biochemistry; 2017 Mar; 56(10):1529-1535. PubMed ID: 28221772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.
    Liu C; Chambers HF
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3040-5. PubMed ID: 14506006
    [No Abstract]   [Full Text] [Related]  

  • 14. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.
    Price J; Atkinson S; Llewelyn M; Paul J
    Clin Infect Dis; 2009 Apr; 48(7):997-8. PubMed ID: 19260820
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
    Mariani PG; Sader HS; Jones RN
    J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycopeptide-intermediate Staphylococcus aureus: rediscovery of an old problem?
    Cercenado E
    Clin Microbiol Infect; 2000 Oct; 6(10):517-8. PubMed ID: 11168044
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots.
    Kang SL; Rybak MJ
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2832-4. PubMed ID: 8593034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefpirome and vancomycin in combination against gentamicin-susceptible and gentamicin-resistant Staphylococcus aureus.
    Carricajo A; Vermesch R; Aubert G
    Clin Microbiol Infect; 2001 Apr; 7(4):218-26. PubMed ID: 11422245
    [No Abstract]   [Full Text] [Related]  

  • 19. Screening for vancomycin intermediate--resistant Staphylococcus aureus among clinical isolates of MRSA.
    Sonavane A; De A; Mathur M
    Indian J Med Microbiol; 2007 Jan; 25(1):79-80. PubMed ID: 17377368
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of heteroresistance among Staphylococcus aureus isolates with vancomycin MICs of 2 micrograms per milliliter by automated testing.
    Satola SW; Caliendo AM; Farley MM; Patel JB; Burd EM
    J Clin Microbiol; 2009 Aug; 47(8):2680-1. PubMed ID: 19553587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.